Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director
— Gene Therapy Veteran to Enhance Company’s DNA-Based Therapeutic Development — ANN ARBOR, Mich., April 18, 2012 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE Amex: SYN), a developer of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, announced today that Michael Kaleko, M.D., Ph.D., has joined the Company as Scientific Director. Dr. Kaleko has worked […]
Synthetic Biologics Appoints Michael Kaleko, M.D., Ph.D., as Scientific Director Read More »